Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.

@article{Berenson2006EfficacyAS,
  title={Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.},
  author={James R Berenson and Ralph V. Boccia and David Siegel and Marek Bozdech and Alberto Bessudo and Edward A. Stadtmauer and J Talisman Pomeroy and Ronald Steis and Marshall S. Flam and Jose Lutzky and Syed Jilani and Joseph Volk and Siu Fun Wong and Robert Moss and Ravi Patel and Delina Ferretti and Kit Russell and Robert Louie and Howard S. Yeh and Regina A. Swift},
  journal={British journal of haematology},
  year={2006},
  volume={135 2},
  pages={
          174-83
        }
}
We assessed the safety and efficacy of melphalan, arsenic trioxide (ATO) and ascorbic acid (AA) (MAC) combination therapy for patients with multiple myeloma (MM) who failed more than two different prior regimens. Patients received melphalan (0.1 mg/kg p.o.), ATO (0.25 mg/kg i.v.) and AA (1 g i.v) on days 1-4 of week 1, ATO and AA twice weekly during weeks 2-5 and no treatment during week 6 of cycle 1; during cycles 2-6, the schedule remained the same except ATO and AA were given twice weekly in… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors

Martin J. Edelman, Rena Lapidus, +4 authors Jogarao Gobbru
  • Cancer Chemotherapy and Pharmacology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND